Skip to main content
Equibles
INKT logo

INKT

MiNK Therapeutics, Inc.
$10.55 -0.07 (-0.66%) At close · Jul 8
Going-concern doubt — flagged May 15, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the completion of anticipated funding is not entirely within the Company’s control, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q.”
View the 10-Q filed May 15, 2026
Market Cap
$52.56M
Shares
4,981,899

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.55 Open$10.61 Day$10.55–11.00 52W$7.20–76.00 Avg vol 30d34K Short int116K · 2.3% float · 2.7d Short vol45% Last earningsMay 15, 2026 DataOct 2021–Jul 2026 Filing10-Q · May 15
Equibles Rating blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 16.9 · calm Equity put/call 0.86
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −12%
below
Price vs 50-day avg −8%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 5%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −7%
trailing
6-month return −11%
trailing
YTD return −5%
this year
Relative strength −18%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $12 › 200d $12 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +5 funds added
Insider flow Distributing
Net -$19.1K over 90 days · 100% sells
Short interest Falling
2.33% of float · ▼ -0.5% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
23 holders — mid 1-yr range
Squeeze score 55
elevated · 0–100
Fundamentals
Weak
EPS growth −2%
Y/Y
Free cash flow $-6.0M
Balance sheet $13.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 739%
annualized · 1-yr
Max drawdown −87%
past year
ATR 7.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
Next earnings call
Aug 25, 2026 Est · unconfirmed · in 7 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 15, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Technicals

      trend & momentum for long-term holders Sell
      4 · 2 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −12% Bearish
      Price vs 50-day avg
      −8% Bearish
      RSI (14)
      39 Neutral
      MACD trend
      Negative Bearish
      52-week position
      5% Bearish
      Volume (OBV)
      Bullish div. Bullish
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $12 › 200d $12 — 200d above 50d
      Institutional flow Distributing
      -4% holders QoQ · +5 funds added
      Insider flow Distributing
      Net -$19.1K over 90 days · 100% sells
      Short interest Falling
      2.33% of float · ▼ -0.5% MoM · 2.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      23 holders — mid 1-yr range
      Price context
      position in its 52-week range
      52-wk low $7 Now $11 · 5% 52-wk high $76
      vs 200-day avg -12% vs 50-day avg -8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      INKT
      MiNK Therapeutics, Inc.
      this stock
      		$52.56M -5.4% — — 2.3%
      ONC
      BeOne Medicines Ltd.
      		 $436.30B -0.6% +22179.2% 887.9 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $126.50B +9.9% +46.2% 29.6 1.8%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $69.50B -14.0% +20.8% 16.2 3.2%
      ARGX
      Argenx SE
      		 $57.20B +8.8% — — 2.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      23
      % held
      2.5%
      Net QoQ
      -26.2K sh
      Top holder
      VANGUARD CAPITAL MANAGEME…
      Held Float
      View
      Held by Funds
      Fund positions
      7
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      115.8K
      Days to cover
      2.7d
      Change
      -610 sh
      View
      Short Volume
      Short vol %
      45%
      As of
      Jul 8, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.8K
      Value
      $34.8K
      As of
      Jun 12, 2026
      View
      Off-Exchange
      Off-exchange %
      53.5%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$19.1K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Net income (FY)
      $-12.5M
      EPS diluted
      $-2.93
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 23, 2026
      This year
      9
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 15, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      INKT -9.8% -7.0% -10.6% -9.8% -5.4%
      SPY -0.2% +0.8% +7.4% -0.2% +9.3%
      vs SPY -9.6% -7.8% -18.0% -9.6% -14.7%
      Key facts CIK 1840229 CUSIP 603693201 13F (30d) 2 filings 1 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)